Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 in Heart Failure (Phase II)
CTR20240570Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of xxb750 in heart failure (HF), sponsored by Novartis. Started Feb 2024; status: terminated.
02
Drugs
xxb750
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on CTR20240570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240570.